n
decemb
novel
pneumonia
syndrom
identifi
patient
cluster
around
huanan
seafood
market
wuhan
china
next
gener
sequenc
use
identifi
novel
coronaviru
known
sever
acut
respiratori
syndrom
coronaviru
bronchoalveolar
lavag
fluid
three
patient
infect
lead
syndrom
coronaviru
diseas
rapid
intern
spread
potenti
lethal
viru
caus
global
concern
case
death
report
date
summar
latest
insight
biolog
implic
anesthesiologist
periop
intens
care
set
rel
assort
virus
caus
human
upper
respiratori
tract
infect
group
virus
caus
lower
respiratori
tract
infect
smaller
includ
influenza
parainfluenza
respiratori
syncyti
viru
cytomegaloviru
hantaviru
infect
mostli
limit
tracheobronch
healthi
individu
caus
sever
viral
pneumonia
immunocompromis
patient
influenza
one
bestknown
caus
pneumonia
intens
care
unit
icu
present
frequent
relat
bacteri
superinfect
staphylococcu
aureu
rariti
viral
pneumonia
attribut
type
cell
virus
infect
term
tropism
thu
common
influenza
strain
like
target
cell
trachea
bronchi
influenza
pneumonia
particularli
link
avian
strain
like
skip
upper
respiratori
epithelium
infect
alveolar
epitheli
cell
lower
respiratori
tract
betacoronaviru
famili
includ
origin
sever
acut
respiratori
syndrom
sar
viru
well
middl
east
respiratori
syndromerel
coronaviru
mer
endem
human
pathogen
common
caus
cold
includ
betacoronavirus
around
yr
outbreak
lethal
strain
sarscov
middl
east
respiratori
syndromerel
coronaviru
ad
notorieti
sarscov
middl
east
respiratori
syndromerel
coronaviru
like
origin
bat
sarscov
use
civet
intermediari
host
middl
east
respiratori
syndromerel
coronaviru
pass
though
camel
pangolin
also
known
scali
anteat
implic
passag
human
basi
sequenc
similar
pangolin
coronavirus
variabl
clinic
manifest
caus
distinct
coronaviru
strain
attribut
structur
differ
viru
protein
affect
tropism
replic
corona
descript
refer
crownlik
halo
viral
spike
protein
observ
electron
microscopi
fig
variat
sprotein
determin
protein
coronavirion
use
enter
cell
earli
investig
suggest
use
tissu
angiotensin
convert
receptor
trait
share
sar
middl
east
respiratori
syndromerel
coronaviru
common
endem
human
coronavirus
angiotensin
convert
special
section
express
lower
respiratori
tract
bronchi
well
enterocyt
small
intestin
thu
angiotensin
convert
depend
may
explain
clinic
present
lower
respiratori
tract
infect
enter
angiotensin
convert
express
vascular
endothelium
cardiac
myocyt
also
implic
acut
cardiac
injuri
result
anim
model
angiotensin
convert
enzym
inhibitor
angiotensinreceptor
blocker
increas
angiotensin
convert
express
activ
respect
lead
specul
medic
could
possibl
potenti
infect
major
cardiolog
societi
recommend
chang
renin
angiotensin
aldosteron
system
antagonist
treatment
base
risk
time
site
express
angiotensin
convert
tongu
part
genitourinari
tract
clinic
signific
find
unclear
bind
sprotein
angiotensin
convert
like
contribut
directli
pathogenesi
result
downregul
angiotensin
convert
increas
product
angiotensin
ii
result
increas
pulmonari
vascular
permeabl
angiotensin
convert
appear
univers
express
human
may
genet
variat
regul
angiotensin
convert
express
could
lead
differenti
suscept
across
popul
genotyp
viral
bind
angiotensin
convert
viru
may
endocytos
directli
fuse
cell
membran
fig
positivesens
viral
rna
transcript
translat
host
cell
yield
two
polypeptid
polypeptid
subsequ
divid
viral
proteas
yield
viral
replic
machineri
coronavirus
employ
multipl
mechan
shield
viral
rna
host
detect
subsequ
induct
antivir
interferon
respons
includ
direct
antagon
interferon
signal
protein
replic
viral
rna
doubl
membran
vesicl
nonetheless
strongli
induc
cytokin
chemokin
includ
tumor
necrosi
macrophag
inflammatori
suggest
broad
type
type
helper
tcell
respons
remain
uncertain
extent
direct
viral
cytotox
versu
host
cytokin
storm
immun
respons
contribut
morbid
initi
coronaviru
infect
immun
respons
appear
effect
control
viral
infect
suggest
vaccin
feasibl
import
caveat
anim
vaccin
model
antibodi
respons
wane
quickli
indic
immun
respons
might
longlast
also
one
mous
coronaviru
model
sar
natur
killer
cell
antibodi
interferon
respons
benefici
tcell
respons
paradox
worsen
outcom
accordingli
vaccin
need
demonstr
safeti
effect
widespread
adopt
incub
period
appear
day
initi
report
demonstr
rapid
persontoperson
viral
transmiss
number
infect
individu
doubl
everi
day
viral
evolut
pattern
infer
viral
gene
sequenc
variat
suggest
much
viral
transmiss
occur
unit
state
undiagnos
two
case
report
week
apart
could
potenti
repres
cluster
hundr
infect
two
distinct
group
sequenc
identifi
ltype
repres
case
wuhan
ancestr
stype
found
case
outsid
wuhan
postul
stype
could
less
sever
thu
capabl
rapid
spread
less
neg
select
pressur
major
patient
infect
present
fever
first
symptom
common
symptom
onset
ill
includ
cough
fatigu
less
commonli
report
symptom
includ
palpit
headach
diarrhea
subset
patient
develop
dyspnea
day
hospit
commonli
report
hematolog
laboratori
abnorm
leukopenia
lymphopenia
caus
leukopenia
well
understood
could
relat
bone
marrow
suppress
lymphocyt
sequestr
apoptosi
clinic
spectrum
case
rang
asymptomat
critic
ill
major
patient
mild
symptom
good
prognosi
patient
develop
pneumonia
acut
respiratori
distress
syndrom
ard
cardiac
injuri
renal
injuri
multiorgan
failur
day
hospit
subset
patient
requir
admiss
icu
respiratori
support
noninvas
invas
ventil
potenti
extracorpor
membran
oxygen
summari
symptom
complic
treatment
initi
wave
case
seri
public
present
tabl
concern
anesthesiologist
periop
set
patient
present
minim
respiratori
symptom
one
initi
case
seri
patient
abdomin
symptom
admit
surgic
servic
infect
least
healthcar
provid
abdomin
symptom
may
reflect
angiotensin
convert
express
small
intestin
potenti
underappreci
sinc
patient
gastrointestin
symptom
may
test
inde
may
transmit
via
fecalor
rout
via
contamin
surfac
pneumonia
abnorm
chest
comput
tomographi
imag
detect
almost
hospit
patient
characterist
radiograph
find
ground
glass
opac
typic
bilater
peripher
coexist
consolid
cordlik
opac
progress
revers
halo
crazypav
radiolog
pattern
may
becom
appar
notabl
radiolog
featur
rare
lymphadenopathi
nodul
pleural
effus
cavit
would
potenti
suggest
patholog
diagnosi
revers
transcriptasepolymeras
chain
reaction
test
standard
assay
throat
swab
nasal
swab
sampl
commonli
use
revers
transcriptasepolymeras
chain
reaction
revers
transcriptasepolymeras
chain
reaction
use
test
confirm
diagnosi
limit
sampl
collect
kit
perform
total
posit
rate
revers
transcriptasepolymeras
chain
reaction
throat
swab
sampl
report
initi
present
serial
revers
transcriptasepolymeras
chain
reaction
test
inclus
lower
airway
sampl
improv
sensit
test
commerci
endocytosi
potenti
target
chloroquin
prevent
endosom
acidif
trigger
viral
membran
fusion
chloroquin
may
also
modifi
termin
glycosyl
inhibit
coronaviru
bind
viral
rna
transcrib
gener
polyprotein
cleav
proteas
gener
viral
replic
machineri
polyprotein
cleav
form
replicationtranscript
protein
complex
rtc
viral
proteas
proteas
postul
target
human
immunodefici
viru
proteas
inhibitor
lopinavir
ritonavir
although
silico
studi
question
theori
viral
rna
replic
transcrib
doubl
membran
vesicl
dmv
replicationtranscript
protein
complex
includ
rnadepend
rna
polymeras
put
target
remdesivir
viral
mrna
translat
virion
assembl
endoplasm
reticulum
golgi
avail
molecular
test
endem
coronavirus
filmarray
respiratori
panel
biofir
diagnost
usa
detect
current
expect
ad
soon
chest
comput
tomographi
may
higher
sensit
infect
sensit
high
one
studi
base
challeng
revers
transcriptasepolymeras
chain
reaction
test
comput
tomographi
imag
propos
primari
tool
detect
hospit
patient
epidem
area
howev
within
first
day
symptom
onset
major
patient
may
normal
comput
tomographi
imag
thu
earli
diseas
cours
may
diagnost
suffici
sensit
exclud
patholog
find
report
case
mani
patholog
find
similar
seen
coronavirusassoci
sever
acut
respiratori
syndrom
caus
sarscov
middl
east
respiratori
syndromerel
coronaviru
inflammatori
infiltr
hyalin
membran
format
find
inspiss
spheric
secret
fibromyxoid
exud
promin
infect
accumul
thick
secret
like
caus
decreas
alveolar
ga
exchang
predispos
respiratori
failur
suggest
potenti
role
airway
clearanc
bronchial
hygien
treatment
full
ramif
infect
yet
understood
earli
work
point
wide
varieti
psychiatr
complic
affect
patient
famili
provid
larger
commun
relat
anxieti
isol
frustrat
stigma
guilt
diseas
also
pose
increas
risk
specif
subpopul
transplant
candid
recipi
patient
cancer
highlight
publish
case
seri
wide
variat
clinic
present
rang
symptom
intract
ard
shock
determin
vari
outcom
remain
unknown
experi
virus
suggest
variat
dose
viral
inoculum
rout
inocul
underli
immun
statu
patient
lead
wide
variabl
host
respons
higher
viral
load
random
sampl
identifi
individu
greater
symptom
burden
influenza
greater
mortal
adenovir
pneumonia
time
moder
viral
load
detect
nasal
swab
week
onset
symptom
asymptomat
individu
attribut
risk
higher
viral
inocula
difficult
quantifi
realworld
set
higher
viral
load
critic
ill
patient
pose
least
theoret
risk
healthcar
provid
major
risk
factor
mortal
among
earli
report
case
old
age
underli
na
na
na
na
na
na
na
retrospect
hospit
zhejiang
provinc
china
na
na
na
na
na
na
na
retrospect
hospit
singapor
na
na
na
na
na
na
na
ard
acut
respiratori
distress
syndrom
ecmo
extracorpor
membran
oxygen
icu
intens
care
unit
na
applic
report
respiratori
diseas
reason
age
associ
unknown
multipl
theori
extrapol
hostpathogen
biolog
exampl
immunosenesc
could
contribut
increas
risk
among
age
individu
age
frequenc
naiv
b
cell
diminish
impli
less
capac
recogn
adapt
novel
antigen
time
age
immun
cell
less
prolif
function
capac
even
respond
known
antigen
agerel
chang
cellular
immun
manifest
decreas
vaccin
effect
wors
outcom
set
influenza
respiratori
syncyti
viru
herp
zoster
infect
demonstr
mous
model
coronaviru
infect
lung
age
airway
epithelium
restor
capac
also
diminish
telomer
dysfunct
one
biolog
mechan
age
primarili
manifest
pulmonari
fibrosi
also
restrict
leukocyt
prolifer
conceiv
poor
outcom
could
link
short
telomer
report
pulmonari
fibrosi
ard
sepsi
also
possibl
younger
individu
may
differenti
suscept
interestingli
rat
lung
angiotensin
convert
express
decreas
age
children
also
could
benefit
immun
develop
coronaviru
infect
inde
modest
crossreact
observ
endem
coronavirus
sarscov
potenti
protect
crossreact
immun
would
limit
age
immunosenesc
fecalor
transmiss
result
milder
gastroenter
present
also
conceiv
children
could
subsequ
protect
respiratori
syndrom
current
specul
caus
variat
present
mechan
like
hold
import
clue
inform
manag
therapeut
patient
appear
rel
mild
diseas
cours
subset
develop
hypoxem
respiratori
failur
imag
pattern
consist
diffus
viral
pneumon
organ
pneumonia
diffus
alveolar
damag
true
incid
sever
pulmonari
diseas
associ
yet
clear
sever
studi
hubei
provinc
report
icu
admiss
rate
among
hospit
patient
confirm
ard
diagnosi
patient
admit
icu
tabl
among
patient
develop
dyspnea
hypoxemia
median
time
onset
symptom
develop
dyspnea
appear
day
ard
develop
smaller
subset
patient
day
manag
sever
hypoxemia
drawn
manag
ard
also
inform
experi
sarscov
middl
east
respiratori
syndromerel
coronaviru
outbreak
world
health
organ
publish
practic
guidelin
clinic
manag
sever
respiratori
infect
sever
group
also
publish
practic
recommend
care
patient
ard
treatment
patient
ard
made
complex
due
necessari
infect
control
intervent
use
isol
room
need
care
provid
wear
appropri
person
protect
equip
transmiss
patient
healthcar
worker
report
infect
control
primari
import
protect
healthcar
worker
prevent
spread
world
health
organ
guidelin
recommend
addit
routin
standard
precaut
provid
use
droplet
contact
precaut
care
patient
confirm
suspect
infect
addit
airborn
precaut
aerosolgener
procedur
intub
bronchoscopi
suction
cardiopulmonari
resuscit
perform
addit
guidelin
frontlin
report
group
hubei
provinc
suggest
mani
provid
util
airborn
precaut
time
care
patient
addit
safeti
measur
select
patient
respiratori
failur
present
hypoxemia
adequ
treat
low
flow
nasal
cannula
oxygen
convent
facemask
trial
either
noninvas
posit
pressur
ventil
heat
humidifi
high
flow
nasal
cannula
oxygen
may
reason
endotrach
intub
mechan
ventil
world
health
organ
manag
guidelin
among
other
suggest
trial
limit
durat
h
avoid
unrecogn
sever
respiratori
decompens
requir
emerg
intervent
use
high
flow
nasal
cannula
noninvas
posit
pressur
ventil
contraind
patient
hemodynam
instabl
multiorgan
failur
alter
mental
statu
high
flow
nasal
cannula
provid
oxygen
patient
high
flow
rate
add
low
cm
h
posit
endexpiratori
pressur
peep
effect
reduc
work
breath
patient
acut
respiratori
failur
high
flow
nasal
cannula
use
treat
ard
good
safeti
profil
given
recent
clinic
introduct
littl
data
outbreak
guid
use
associ
respiratori
failur
one
studi
patient
ard
random
receiv
initi
high
flow
nasal
cannula
noninvas
posit
pressur
ventil
convent
oxygen
therapi
use
high
flow
nasal
cannula
significantli
reduc
intub
rate
overal
patient
special
section
random
high
flow
nasal
cannula
arm
lower
mortal
rate
patient
moder
sever
ard
less
like
requir
convers
mechan
ventil
random
high
flow
nasal
cannula
arm
trial
systemat
review
use
high
flow
nasal
cannula
ard
find
differ
mortal
intub
rate
compar
usual
care
found
high
flow
nasal
cannula
well
toler
patient
use
novel
indic
ratio
oxygen
saturationfract
inspir
oxygen
respiratori
rate
may
help
predict
clinic
deterior
need
intub
high
flow
nasal
cannula
use
given
exist
literatur
base
use
high
flow
nasal
cannula
initi
strategi
treatment
respiratori
failur
appear
reason
patient
close
monitor
worsen
respiratori
distress
world
health
organ
guidelin
other
recommend
avoid
high
flow
nasal
cannula
use
patient
sever
worsen
hypercapnia
hemodynam
instabl
multiorgan
failur
alter
mental
statu
although
guidelin
recommend
use
noninvas
posit
pressur
ventil
manag
acut
respiratori
failur
due
cardiogen
pulmonari
edema
patient
chronic
obstruct
pulmonari
diseas
copd
exacerb
lead
respiratori
acidosi
recommend
made
regard
use
noninvas
posit
pressur
ventil
ard
use
noninvas
posit
pressur
ventil
patient
ard
evalu
sever
larg
trial
recent
studi
report
high
greater
rate
noninvas
posit
pressur
ventil
failur
lead
invas
mechan
ventil
patient
moder
sever
ard
studi
noninvas
posit
pressur
ventil
failur
associ
increas
mortal
use
noninvas
posit
pressur
ventil
patient
sever
ard
pao
fio
less
mmhg
sever
author
suggest
increas
mortal
observ
noninvas
posit
pressur
ventil
use
patient
sever
ard
ultim
requir
invas
mechan
ventil
may
explain
noninvas
posit
pressur
ventil
delay
time
need
intub
lung
injuri
caus
uncontrol
high
tidal
volum
noninvas
posit
pressur
ventil
limit
data
suggest
noninvas
posit
pressur
ventil
deliv
via
helmet
patient
ard
failur
rate
mortal
may
lower
convent
noninvas
posit
pressur
ventil
facemask
use
helmet
mask
may
addit
benefici
infect
control
perspect
intervent
wide
avail
experi
influenza
epidem
middl
east
respiratori
syndromerel
coronaviru
epidem
also
inform
recommend
use
noninvas
posit
pressur
ventil
larg
observ
studi
patient
report
greater
noninvas
posit
pressur
ventil
failur
rate
increas
mortal
patient
fail
initi
noninvas
posit
pressur
ventil
requir
invas
mechan
ventil
observ
studi
treatment
patient
middl
east
respiratori
syndromerel
coronaviru
report
greater
failur
rate
use
noninvas
posit
pressur
ventil
base
best
avail
data
use
noninvas
posit
pressur
ventil
initi
strategi
treatment
ard
like
reason
subset
patient
mild
ard
copd
exacerb
heart
failur
may
also
contribut
respiratori
distress
patient
close
monitor
improv
worsen
respiratori
distress
substanti
concern
use
noninvas
posit
pressur
ventil
high
flow
nasal
cannula
patient
viral
respiratori
ill
result
increas
product
aerosol
viru
particl
creat
risk
healthcar
worker
contamin
clinic
environ
multipl
studi
sar
epidem
identifi
particip
tracheal
intub
risk
factor
viral
spread
healthcar
worker
noninvas
ventil
identifi
risk
factor
two
small
studi
consid
robust
enough
establish
risk
transmiss
metaanalysi
experiment
studi
exhal
air
dispers
mannequin
isol
room
use
convent
low
flow
nasal
cannula
high
flow
nasal
cannula
continu
posit
airway
pressur
nasal
pillow
full
facemask
demonstr
greater
exhal
air
dispers
convent
low
flow
nasal
cannula
lmin
patient
face
compar
either
high
flow
nasal
cannula
continu
posit
airway
pressur
author
postul
lower
exhal
air
dispers
high
flow
nasal
cannula
continu
posit
airway
pressur
mask
could
relat
tighter
fit
face
modal
also
humidifi
air
gener
modal
could
result
exhal
larger
droplet
shorter
trajectori
due
graviti
use
full
noninvas
posit
pressur
ventil
facemask
might
also
prevent
spread
aerosol
droplet
patient
sneez
cough
thu
risk
method
oxygen
deliveri
patient
respiratori
distress
result
spread
viruscontain
exhal
air
especi
mask
poorli
fit
leak
concern
use
noninvas
posit
pressur
ventil
high
flow
nasal
cannula
specif
lead
wors
environment
contamin
substanti
current
avail
evid
patient
receiv
supplement
oxygen
therapi
care
airborn
isol
room
whenev
possibl
staff
use
full
contact
droplet
airborn
isol
precaut
provid
awar
coronavirus
remain
infecti
inanim
surfac
day
surfac
equip
use
patient
care
disinfect
greater
ethanol
small
surfac
greater
sodium
hypochlorit
larger
surfac
regardless
choic
initi
oxygen
therapi
patient
respiratori
failur
patient
close
monitor
deterior
intub
promptli
avoid
need
emerg
intervent
experi
sar
epidem
suggest
intub
time
healthcar
worker
high
risk
viral
transmiss
infect
patient
odd
ratio
note
howev
sever
healthcar
provid
contract
sar
intub
patient
wear
standard
surgic
facemask
time
intub
strong
evid
link
intub
risk
transmiss
viru
healthcar
worker
proper
airborn
precaut
taken
note
sever
post
hoc
report
sar
epidem
emerg
report
current
epidem
recommend
use
higher
level
person
protect
equip
power
airpurifi
respir
doubl
glove
coveral
foot
cover
hood
perform
aerosol
gener
procedur
intub
appear
evid
support
superior
measur
standard
droplet
contact
aerosol
precaut
even
suggest
use
increas
layer
barrier
precaut
without
strong
evid
support
applic
make
patient
care
challeng
could
increas
risk
contamin
lengthi
complex
person
protect
equip
remov
procedur
applic
full
barrier
precaut
report
take
least
min
ideal
perform
emerg
endotrach
intub
indic
world
health
organ
clinic
guidelin
suggest
perform
experienc
provid
use
airborn
precaut
guidelin
also
recommend
use
modal
nonrebreath
mask
bag
valv
mask
high
flow
nasal
cannula
noninvas
posit
pressur
ventil
preoxygen
oxygen
min
use
rapid
sequenc
induct
possibl
avoid
cough
need
posit
pressur
breath
addit
guidelin
experienti
report
hubei
provinc
larg
echo
recommend
note
data
recent
metaanalysi
note
benefit
use
high
flow
nasal
cannula
periintub
preoxygen
compar
usual
oxygen
therapi
patient
hypoxem
respiratori
failur
howev
high
flow
nasal
cannula
may
benefit
prevent
sever
hypoxemia
intub
prolong
apneic
time
patient
sever
hypoxemia
see
tabl
addit
clinic
recommend
regard
airway
manag
intub
manag
respiratori
failur
ard
caus
us
european
union
recent
releas
unit
kingdom
ard
guidelin
strongli
recommend
use
low
tidal
volum
ventil
mlkg
predict
bodi
weight
useuropean
union
guidelin
less
mlkg
unit
kingdom
guidelin
maintain
plateau
pressur
less
cm
h
permiss
hypercapnia
us
european
union
unit
kingdom
guidelin
also
strongli
recommend
use
prone
posit
greater
h
per
day
patient
sever
moderatesever
unit
kingdom
guidelin
ard
recommend
echo
world
health
organ
guidelin
howev
prone
ventil
resourceintens
intervent
endotrach
tube
line
may
becom
displac
recommend
suffici
human
resourc
expertis
within
medic
center
intervent
perform
safe
world
health
organ
guidelin
manag
echo
unit
kingdom
ard
guidelin
recommend
conserv
fluid
manag
strategi
patient
without
evid
tissu
hypoperfus
useuropean
union
unit
kingdom
ard
guidelin
weakli
recommend
use
higher
peep
moder
sever
ard
unit
kingdom
guidelin
weakli
recommend
use
neuromuscular
blockad
continu
infus
earli
moder
sever
ard
recent
clinic
trial
challeng
recommend
thu
variou
compon
best
clinic
practic
ard
remain
unclear
time
larg
multicent
trial
patient
random
receiv
either
convent
low
peep
ventil
strategi
titrat
peep
strategi
result
high
peep
combin
lung
recruit
maneuv
found
increas
mortal
higher
peep
lung
recruit
maneuv
arm
regard
use
neuromuscular
blockad
recent
multicent
random
trial
found
mortal
benefit
use
earli
moder
sever
ard
advers
cardiovascular
event
paralysi
arm
studi
trial
mind
world
health
organ
guidelin
suggest
cautiou
use
higher
peep
moder
sever
ard
routin
use
neuromuscular
blockad
patient
refractori
hypoxemia
despit
lung
protect
ventil
best
practic
limit
data
guid
effect
use
extracorpor
membran
oxygen
unit
kingdom
ard
guidelin
weakli
recommend
consider
extracorpor
membran
oxygen
patient
sever
ard
refractori
hypoxemia
although
recommend
publish
result
random
control
trial
extracorpor
membran
oxygen
ard
stop
earli
due
lack
statist
signific
mortal
benefit
extracorpor
membran
oxygen
special
section
strict
adher
univers
precaut
time
perform
practic
drill
familiar
provid
appropri
procedur
donningdof
person
protect
equip
nonemerg
emerg
situat
perform
crisi
manag
simul
help
provid
prepar
intub
code
blue
event
isol
room
intub
delay
intub
patient
worsen
respiratori
failur
avoid
emerg
situat
person
protect
equip
must
appli
hast
intub
either
oper
room
icu
wear
least
gown
higher
mask
cap
face
shield
glove
sourc
suggest
power
airpurifi
respir
doubl
glove
boot
coveral
use
power
airpurifi
respir
consid
minim
risk
contamin
remov
power
airpurifi
respir
colleagu
person
protect
equip
champion
check
proper
person
protect
equip
applic
enter
patient
room
oper
room
consid
write
provid
name
gown
hood
worn
make
identif
easier
consid
assembl
intub
kit
need
suppli
advanc
avoid
multipl
entriesexit
isol
room
delay
obtain
necessari
suppli
consid
review
intub
plan
provid
enter
patient
room
minim
number
experienc
personnel
room
whenev
possibl
use
dispos
equip
whenev
possibl
preoxygen
min
oxygen
avoid
manual
ventil
possibl
possibl
use
rapid
sequenc
modifi
rapid
sequenc
induct
avoid
bag
mask
ventil
patient
consid
insert
laryng
mask
airway
prolong
need
mask
patient
anticip
rocuronium
may
prefer
succinylcholin
paralyt
rapid
sequenc
induct
avoid
potenti
paralysi
wear
patient
cough
intub
procedur
prolong
attach
high
effici
hydrophob
filter
mask
endotrach
tube
bag
avoid
awak
fiberopt
intub
possibl
decreas
patient
cough
intub
use
video
laryngoscopi
avail
increas
distanc
patient
intub
provid
put
cuff
immedi
intub
trachea
monitor
intub
success
capnographyus
person
protect
equip
may
make
auscult
stethoscop
difficult
imposs
consid
use
ultrasound
chest
radiograph
confirm
tracheal
rather
bronchial
intub
auscult
may
difficult
imposs
note
standard
sodium
hypochlorit
effect
inactiv
coronaviru
doubl
concentr
sodium
hypochlorit
clearli
label
room
hot
zone
patient
provid
know
put
appropri
person
protect
equip
colleagu
person
protect
equip
champion
check
proper
person
protect
equip
remov
exit
patient
room
oxygen
ventil
manag
use
noninvas
posit
pressur
ventil
high
flow
nasal
cannula
mechan
ventil
singl
airborn
isol
room
consid
patient
supplementari
oxygen
via
nasal
cannula
wear
surgic
mask
tube
consid
use
inlin
suction
system
minim
suction
possibl
frequent
empti
condens
tube
line
consid
use
medic
dexmedetomidin
lidocain
remifentanil
extub
minim
cough
prepostop
care
unit
design
isol
holdingrecoveri
area
ideal
dedic
room
neg
pressur
ventil
consid
requir
patient
provid
wear
mask
periop
set
consid
patient
transport
oper
room
wear
surgic
mask
consid
dedic
hallway
patient
transport
rout
patient
possibl
oper
room
consid
dedic
oper
room
patient
ideal
anteroom
neg
pressur
neg
pressur
oper
room
work
engin
turn
positivepressur
system
consid
use
neg
pressur
isol
icu
room
oper
room
surgeri
necessari
patient
use
dedic
anesthesia
machin
high
effici
hydrophob
filter
inspiratori
expiratori
limb
circuit
chang
filter
everi
h
oper
case
consid
gener
anesthesia
patient
reduc
risk
cough
intub
patient
wear
surgic
mask
minim
staff
handoff
oper
room
ventil
must
complet
clean
use
pay
special
attent
patient
chart
pen
phone
disinfect
code
blue
creat
modular
code
pack
bring
room
prevent
contamin
code
blue
cart
make
need
equip
easili
access
isol
room
emerg
consid
implement
special
design
protect
code
blue
distinguish
code
blue
patient
code
event
design
protect
code
blue
coach
make
sure
care
provid
enter
exit
room
follow
safe
dondoff
procedur
person
protect
equip
periop
clinic
case
epidem
consid
screen
preoper
patient
fever
send
ill
febril
emerg
room
home
appropri
consid
provid
use
contact
droplet
potenti
aerosol
transmiss
precaut
see
patient
preoper
clinic
group
medic
manag
group
howev
reanalysi
data
trial
well
metaanalysi
incorpor
new
trial
data
suggest
extracorpor
membran
oxygen
may
provid
mortal
benefit
patient
sever
ard
small
casecontrol
seri
middl
east
respiratori
syndromerel
coronaviru
outbreak
use
extracorpor
membran
oxygen
refractori
hypoxemia
associ
lower
inhospit
mortal
consid
data
may
reason
refer
patient
refractori
hypoxemia
despit
lung
protect
ventil
extracorpor
membran
oxygen
center
expertis
resourc
properli
manag
complex
patient
patient
respiratori
failur
develop
superimpos
septic
shock
adher
standard
sepsi
treatment
protocol
advis
addit
nonevidencebas
recommend
manag
respiratori
failur
promulg
varieti
guidelin
publish
sourc
larg
focus
minim
viral
spread
healthcar
worker
environ
recommend
includ
minim
ventil
disconnect
use
inlin
cathet
airway
suction
use
high
effici
hydrophob
filter
patient
breath
circuit
avoid
use
nebul
medic
favor
meter
dose
inhal
bronchodil
indic
collect
list
practic
recommend
guid
anesthet
critic
care
manag
patient
found
tabl
tabl
provid
list
organ
offer
updat
guidelin
resourc
provid
care
patient
drug
specif
approv
treatment
multipl
ongo
clinic
trial
number
drug
show
promis
rna
viru
like
human
immunodefici
viru
hiv
ebola
molecul
develop
rna
virus
may
use
target
fig
particular
remdesivir
nucleotid
analog
develop
use
ebola
infect
drug
inhibit
rnadepend
rna
polymeras
use
coronavirion
replic
genom
base
vitro
evid
effect
manufactur
initi
two
phase
clinic
trial
use
remdesivir
trial
no
similar
trial
sever
moder
case
underway
china
trial
no
remdesivir
also
initi
treatment
arm
adapt
clinic
trial
sponsor
nation
institut
allergi
infecti
diseas
trial
adapt
trial
activ
modifi
add
novel
drug
interest
replac
control
arm
current
best
support
regimen
interestingli
antimalaria
drug
chloroquin
also
shown
inhibit
micromolar
concentr
agent
block
viru
infect
entri
postentri
stage
use
therapeut
prophylact
regimen
yr
safeti
profil
includ
promin
neurolog
gastrointestin
side
effect
well
known
among
possibl
mechan
action
alter
ph
endosom
directli
modifi
angiotensin
convert
compar
histor
control
cohort
patient
treat
combin
lopinavirritonavir
significantli
lower
risk
ard
death
combin
lopinavirritonavir
use
case
well
base
sar
data
vitro
effect
howev
clinic
effect
remain
unproven
provid
cogniz
known
side
effect
profil
medic
monitor
hepatotox
hyperglycemia
arrythmia
ongo
clinic
trial
compar
patient
random
lopinavirritonavir
viral
fusion
inhibitor
arbidol
trial
optim
regimen
remain
determin
affect
patient
consid
enrol
clinic
trial
whenev
avail
world
health
organ
center
diseas
control
prevent
recommend
discourag
use
corticosteroid
given
risk
precipit
infecti
noninfecti
complic
secondari
bacteri
infect
hyperglycemia
middl
east
respiratori
syndromerel
coronaviru
patient
steroid
therapi
associ
delay
viral
clearanc
improv
surviv
howev
difficult
account
bia
sicker
patient
like
receiv
steroid
ard
despit
multipl
random
control
studi
corticosteroid
benefit
corticosteroid
remain
equivoc
like
benefit
greater
select
ard
patient
earli
diseas
cours
superimpos
septic
shock
patient
multipl
distinct
radiolog
pattern
diffus
ground
glass
reticul
consolid
suggest
pneumon
diffus
alveolar
damag
organ
pneumonia
cryptogen
organ
pneumonia
steroid
administr
suggest
prevent
progress
hypoxem
respiratori
failur
case
seri
time
requir
steroid
shown
less
relev
organ
pneumonia
identifi
caus
compar
steroid
patient
treat
macrolid
mild
cryptogen
organ
pneumonia
also
demonstr
symptom
resolut
albeit
higher
relaps
rate
case
seri
patient
steroid
macrolid
commonli
use
lack
data
effect
retrospect
analysi
could
confound
indic
steroid
therapi
associ
decreas
risk
death
patient
ard
specif
studi
patient
need
determin
whether
corticosteroid
macrolid
could
benefici
subset
patient
organ
pneumonia
pattern
face
rapidli
emerg
global
threat
sever
reason
optim
futur
control
describ
number
antivir
drug
shown
promis
vitro
even
partial
effect
antivir
could
allow
suffici
reduct
viral
load
immun
system
recov
respond
prevent
lethal
diseas
even
potenti
antivir
could
use
chemoprophylaxi
prevent
transmiss
recent
expos
individu
resist
antivir
develop
quickli
patient
hiv
studi
coronavirus
suggest
might
less
problem
similarli
hiv
readili
evad
cellular
humor
immun
sharpli
limit
vaccin
approach
sarscov
infect
appear
induc
broad
longlast
immun
less
evid
immun
escap
thu
like
evolv
physician
varieti
therapeut
vaccin
option
minim
morbid
mortal
arriv
anesthesiologist
call
upon
provid
support
care
minim
risk
viral
transmiss
other
